The sequential failure to recruit cDC1s and CD8+ T cells into the tumor, due to the presence of PGE-2, leads to disruptions at key steps of the cancer immune cycle, such as the antigen presentation, priming, and activation of T cells, and the trafficking and infiltration of T cells into the tumor. This evidence concerns the gene CD8A and cancer.